|
1
|
Lim DR, Kuk JK, Kim T and Shin EJ:
Comparison of oncological outcomes of right-sided colon cancer
versus left-sided colon cancer after curative resection: Which side
is better outcome? Medicine (Baltimore). 96:e82412017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Labianca R, Beretta GD, Kildani B, Milesi
L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, et
al: Colon cancer. Crit Rev Oncol Hematol. 74:106–133. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petrelli F, Tomasello G, Borgonovo K,
Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G and Barni S:
Prognostic survival associated with left-sided vs right-sided colon
cancer: A systematic review and meta-analysis. JAMA Oncol.
3:211–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meguid RA, Slidell MB, Wolfgang CL, Chang
DC and Ahuja N: Is there a difference in survival between
right-versus left-sided colon cancers? Ann Surg Oncol.
15:2388–2394. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Warschkow R, Sulz MC, Marti L, Tarantino
I, Schmied BM, Cerny T and Güller U: Better survival in right-sided
versus left-sided stage I-III colon cancer patients. BMC Cancer.
16:5542016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu MZ, Pan WT, Lin JZ, Wang ZX, Pan ZZ,
Wang FH, Yang DJ and Xu RH: Comparison of survival between
right-sided and left-sided colon cancer in different situations.
Cancer Med. 7:1141–1150. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin Q, Yang L, Sun YK, Ying JM, Song Y,
Zhang W, Wang JW and Zhou AP: Comparison of 627 patients with
right- and left-sided colon cancer in China: Differences in
clinicopathology, recurrence, and survival. Chronic Dis Transl Med.
3:51–59. 2017.PubMed/NCBI
|
|
8
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diener C, Keller A and Meese E: Emerging
concepts of miRNA therapeutics: From cells to clinic. Trends Genet.
38:613–626. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong S, Golpon H, Zardo P and Borlak J:
miRNAs in lung cancer. A systematic review identifies predictive
and prognostic miRNA candidates for precision medicine in lung
cancer. Transl Res. 230:164–196. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Schooneveld E, Wildiers H, Vergote I,
Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs
in breast cancer and their potential role as prognostic and
predictive biomarkers in patient management. Breast Cancer Res.
17:212015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fang SS, Guo JC, Zhang JH, Liu JN, Hong S,
Yu B, Gao Y, Hu SP, Liu HZ, Sun L and Zhao Y: A P53-related
microRNA model for predicting the prognosis of hepatocellular
carcinoma patients. J Cell Physiol. 235:3569–3578. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stiegelbauer V, Perakis S, Deutsch A, Ling
H, Gerger A and Pichler M: MicroRNAs as novel predictive biomarkers
and therapeutic targets in colorectal cancer. World J
Gastroenterol. 20:11727–11735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schepeler T, Reinert JT, Ostenfeld MS,
Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ,
Kruhøffer M, Laurberg S, et al: Diagnostic and prognostic microRNAs
in stage II colon cancer. Cancer Res. 68:6416–6424. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nosho K, Igarashi H, Nojima M, Ito M,
Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, et
al: Association of microRNA-31 with BRAF mutation, colorectal
cancer survival and serrated pathway. Carcinogenesis. 35:776–783.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Omrane I, Kourda N, Stambouli N, Privat M,
Medimegh I, Arfaoui A, Uhrhammer N, Bougatef K, Baroudi O,
Bouzaienne H, et al: MicroRNAs 146a and 147b biomarkers for
colorectal tumor's localization. Biomed Res Int. 2014:5848522014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gopalan V, Pillai S, Ebrahimi F,
Salajegheh A, Lam TC, Le TK, Langsford N, Ho YH, Smith RA and Lam
AK: Regulation of microRNA-1288 in colorectal cancer: Altered
expression and its clinicopathological significance. Mol Carcinog.
53 (Suppl 1):E36–E44. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu W, Yang Y, Li X, Huang M, Xu F, Ge W,
Zhang S and Zheng S: Multi-omics approach reveals distinct
differences in left- and right-sided colon cancer. Mol Cancer Res.
16:476–485. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng K, Han P, Song W, Wang Z, Zhang F,
Xie H, Zhao W, Xu H, Cai Y, Rong Z, et al: Plasma metabolomic
profiling distinguishes right-sided from left-sided colon cancer.
Clin Chim Acta. 487:357–362. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang JX, Song W, Chen ZH, Wei JH, Liao
YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, et al: Prognostic and
predictive value of a microRNA signature in stage II colon cancer:
A microRNA expression analysis. Lancet Oncol. 14:1295–1306. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gu H, Gu S, Zhang X, Zhang S, Zhang D, Lin
J, Hasengbayi S and Han W: miR-106b-5p promotes aggressive
progression of hepatocellular carcinoma via targeting RUNX3. Cancer
Med. 8:6756–6767. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang F, Sun Z, Wang D and Du T:
MiR-106b-5p regulates esophageal squamous cell carcinoma
progression by binding to HPGD. BMC Cancer. 22:3082022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zong S, Liu X, Zhou N and Yue Y: E2F7,
EREG, miR-451a and miR-106b-5p are associated with the cervical
cancer development. Arch Gynecol Obstet. 299:1089–1098. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei K, Pan C, Yao G, Liu B, Ma T, Xia Y,
Jiang W, Chen L and Chen Y: MiR-106b-5p promotes proliferation and
inhibits apoptosis by regulating BTG3 in non-small cell lung
cancer. Cell Physiol Biochem. 44:1545–1558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bonnu CH, Ramadhani AN, Saputro RB,
Sesotyosari SL, Danarto R, Astuti I and Haryana SM: The potential
of hsa-mir-106b-5p as liquid biomarker in prostate cancer patients
in Indonesia. Asian Pac J Cancer Prev. 22:837–842. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Farré PL, Duca RB, Massillo C, Dalton GN,
Graña KD, Gardner K, Lacunza E and De Siervi A: MiR-106b-5p: A
master regulator of potential biomarkers for breast cancer
aggressiveness and prognosis. Int J Mol Sci. 22:111352021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhuang M, Zhao S, Jiang Z, Wang S, Sun P,
Quan J, Yan D and Wang X: MALAT1 sponges miR-106b-5p to promote the
invasion and metastasis of colorectal cancer via SLAIN2 enhanced
microtubules mobility. EBioMedicine. 41:286–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen H, Yang J, Huang Q, Jiang MJ, Tan YN,
Fu JF, Zhu LZ, Fang XF and Yuan Y: Different treatment strategies
and molecular features between right-sided and left-sided colon
cancers. World J Gastroenterol. 21:6470–6478. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salem ME, Weinberg BA, Xiu J, El-Deiry WS,
Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ and Marshall
JL: Comparative molecular analyses of left-sided colon, right-sided
colon, and rectal cancers. Oncotarget. 8:86356–86368. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee G, Malietzis G, Askari A, Bernardo D,
Al-Hassi H and Clark S: Is right-sided colon cancer different to
left-sided colorectal cancer?-A systematic review. Eur J Surg
Oncol. 41:300–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weiss JM, Pfau PR, O'Connor ES, King J,
LoConte N, Kennedy G and Smith MA: Mortality by stage for
right-versus left-sided colon cancer: Analysis of surveillance,
epidemiology, and end results-Medicare data. J Clin Oncol.
29:4401–4409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Benedix F, Kube R, Meyer F, Schmidt U,
Gastinger I and Lippert H; Colon/Rectum Carcinomas (Primary Tumor)
Study Group, : Comparison of 17,641 patients with right- and
left-sided colon cancer: differences in epidemiology, perioperative
course, histology, and survival. Dis Colon Rectum. 53:57–64. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Suttie S, Shaikh I, Mullen R, Amin A,
Daniel T and Yalamarthi S: Outcome of right- and left-sided colonic
and rectal cancer following surgical resection. Colorectal Dis.
13:884–889. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wray CM, Ziogas A, Hinojosa MW, Le H,
Stamos MJ and Zell JA: Tumor subsite location within the colon is
prognostic for survival after colon cancer diagnosis. Dis Colon
Rectum. 52:1359–1366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Derwinger K and Gustavsson B: Variations
in demography and prognosis by colon cancer location. Anticancer
Res. 31:2347–2350. 2011.PubMed/NCBI
|
|
38
|
Lech G, Słotwiński R, Słodkowski M and
Krasnodębski IW: Colorectal cancer tumour markers and biomarkers:
Recent therapeutic advances. World J Gastroenterol. 22:1745–1755.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jorgensen ML, Young JM and Solomon MJ:
Optimal delivery of colorectal cancer follow-up care: Improving
patient outcomes. Patient Relat Outcome Meas. 6:127–138.
2015.PubMed/NCBI
|
